Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review [PDF]
Therapeutic Advances in Hematology, 2021 The treatment of immune thrombocytopenia (ITP) in adults has evolved rapidly over the past decade. The second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag are approved for the treatment of chronic ITP ...
Nikki Agarwal, Ankit Mangla
doaj +2 more sources
Successful Treatment of Evans Syndrome Onset With Zanubrutinib in Combination With Romiplostim During Venetoclax Treatment in a Patient With Chronic Lymphocytic Leukemia: A Case Report [PDF]
Clinical Case ReportsChronic lymphocytic leukemia (CLL) can be complicated by autoimmune cytopenias, including autoimmune hemolytic anemia and immune thrombocytopenia (ITP), as observed in Evans syndrome. We report the case of a 75‐year‐old man with CLL who developed steroid‐
Vanessa Innao +4 more
doaj +2 more sources
Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS [PDF]
International Journal of Analytical Chemistry, 2020 Lusutrombopag is a second oral thrombopoietin (TPO) receptor agonist that selectively acts on human TPO receptors. In the study, UPLC-MS/MS was used to establish a selective and sensitive method to determine lusutrombopag with poziotinib as IS (internal ...
Bo Wang +10 more
doaj +2 more sources
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia [PDF]
Therapeutic Advances in Hematology, 2019 Primary immune thrombocytopenia (ITP) is a bleeding disorder that conventionally has been treated with steroids or other immunosuppressive treatments.
José R. González-Porras +2 more
doaj +2 more sources
Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation‐Induced Premature Aging [PDF]
Pharmacology Research & PerspectivesEnvironmental stressors, such as ionizing radiation, accelerate aging by causing DNA damage and triggering pathways that lead to cell cycle arrest, apoptosis, and subsequent inflammation.
Masaru Yamaguchi +3 more
doaj +2 more sources
Thrombopoietin receptor agonists in hereditary thrombocytopenias [PDF]
Journal of Thrombosis and Haemostasis, 2018 Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought.
Rodeghiero, F. +2 more
openaire +3 more sources
Health Technology Assessment, 2020 Background: There have been no licensed treatment options in the UK for treating thrombocytopenia in people with chronic liver disease requiring surgery.
Nigel Armstrong +15 more
doaj +1 more source
Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism
Clinical Pathology, 2022 Thrombopoietin (TPO)-receptor agonists have heralded a paradigm shift in the treatment of refractory immune thrombocytopenia (ITP). Reactive thrombocytosis has been described as a secondary effect of such therapies.
Rithin Nedumannil +2 more
doaj +1 more source
Cancer Pathogenesis and Therapy, 2023 Immune thrombocytopenia (ITP) is common in the elderly. Because of the coexistence of multiple diseases, there are many reservations regarding corticosteroid use in the elderly. Thrombopoietin (TPO) and its analogs can promote platelet production, but it
Jundong Zhang +3 more
doaj +1 more source
Platelets, 2022 Impaired platelet production is a mechanism of immune thrombocytopenia (ITP). Morphological abnormalities of megakaryocytes (MKs) are sometimes observed in this disease.
Ondine Walter +15 more
doaj +1 more source